slides · global inventory
Turn
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 37,461
Current window 24,661-24,690
Pages 1,249
Rows per page 30
Beat
24,661-24,690 of 37,461
10
Includes footnotes regarding restricted cash, FFI acquisition, share registration, and adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
11
Includes footnotes detailing stock-based compensation components.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
12
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
13
Includes footnotes regarding order conditions and currency units.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
06
Uses a Venn diagram to illustrate the intersection of Kinase Resistance and Kinase Selectivity.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a molecular pathway diagram and a Western blot image as evidence.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Clinical trial NCT05226507 status update.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
Uses a structural biology diagram to illustrate mechanism of action.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Uses waterfall-style bar charts to show peer distribution with the subject company highlighted.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
08
The slide uses a dual-chart layout to compare 'Prior Rate Cycle' (2015-2019) vs 'Current Rate Cycle' (2021-2023).Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could BeLoop · Analogy1 hit
09
The slide uses scatter plots to benchmark 'Old Second' against a 'Community Bank Median' across two key metrics.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could BeLoop · Analogy1 hit
10
Includes three combo charts showing historical trends in credit metrics.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
11
Includes a performance summary table showing CAGR for Share Price and TBVPS.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
12
Data covers Q2 2019 through Q2 2023.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
13
The slide displays historical performance of capital ratios from Q2 2019 to Q2 2023.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
11
The slide uses a linear process flow to describe the core value proposition.OmniAb | Investor Presentation Deck | 35 slides · OmniAb
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide uses a process-oriented framework to categorize various proprietary technologies.OmniAb | Investor Presentation Deck | 35 slides · OmniAb
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
OmniAb | Investor Presentation Deck | 35 slidesOmniAb | Investor Presentation Deck | 35 slides · OmniAb
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide uses a process-oriented header (Create, Screen, Deliver) and lists specific proprietary technologies (OmniRat, OmniMouse, etc.) alongside value propositions.OmniAb | Investor Presentation Deck | 35 slides · OmniAb
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit